Skip to content

DBVT

DBV Technologies SA

NASDAQ · Healthcare · Biotechnology · FR

$9.94
−1.68%
Ask drillr

Year over year

Reported trailing growth

Revenue
-100.0%
EBITDA
-66.8%
EBIT
-60.2%
EPS
-3.5%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+79.8%
EPS
+75.0%

Three-year CAGR

Revenue
—
EBITDA
-29.6%
EBIT
-22.0%
Net income
-29.2%
EPS
-41.7%
Free cash flow
-13.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026